UBS Group’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,660
| Closed | -$363K | – | 9117 |
|
|
2020
Q3 | $363K | Buy |
2,660
+1,522
| +134% | +$162K | ﹤0.01% | 4406 |
|
|
2020
Q2 | $110K | Buy |
1,138
+873
| +329% | +$72.8K | ﹤0.01% | 5227 |
|
|
2020
Q1 | $12K | Sell |
265
-5,576
| -95% | -$357K | ﹤0.01% | 6845 |
|
|
2019
Q4 | $426K | Buy |
5,841
+5,656
| +3,057% | +$343K | ﹤0.01% | 4984 |
|
|
2019
Q3 | $10K | Sell |
185
-1,351
| -88% | -$71.8K | ﹤0.01% | 7190 |
|
|
2019
Q2 | $77K | Buy |
1,536
+1,351
| +730% | +$65.8K | ﹤0.01% | 5580 |
|
|
2019
Q1 | $10K | Sell |
185
-908
| -83% | -$41.8K | ﹤0.01% | 6846 |
|
|
2018
Q4 | $53K | Buy |
1,093
+423
| +63% | +$23.3K | ﹤0.01% | 6049 |
|
|
2018
Q3 | $44K | Sell |
670
-2,088
| -76% | -$123K | ﹤0.01% | 6257 |
|
|
2018
Q2 | $137K | Sell |
2,758
-48,217
| -95% | -$2.33M | ﹤0.01% | 5223 |
|
|
2018
Q1 | $2.49M | Buy |
50,975
+50,094
| +5,686% | +$2.6M | ﹤0.01% | 2960 |
|
|
2017
Q4 | $37K | Sell |
881
-81,240
| -99% | -$3.13M | ﹤0.01% | 6090 |
|
|
2017
Q3 | $3.52M | Buy |
+82,121
| New | +$2.62M | ﹤0.01% | 2560 |
|
|
2017
Q2 | – | Sell |
-390
| Closed | -$5K | – | 8153 |
|
|
2017
Q1 | $5K | Sell |
390
-1,597
| -80% | -$20.5K | ﹤0.01% | 7020 |
|
|
2016
Q4 | $26K | Buy |
+1,987
| New | +$30.6K | ﹤0.01% | 6351 |
|
|
2016
Q3 | – | Sell |
-651
| Closed | -$8K | – | 8077 |
|
|
2016
Q2 | $8K | Buy |
+651
| New | +$8.14K | ﹤0.01% | 6922 |
|
UBS Group's MYOK Position: Q4 2020 in Review
UBS Group sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 2,660 shares — an estimated $363K sold.
UBS Group first reported a position in MYOK in Q2 2016 and held it in 16 quarters. The position peaked at $3.52M in Q3 2017. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- UBS Group reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- UBS Group sold 2,660 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $363K.
- UBS Group first reported a position in MyoKardia, Inc. Common Stock in Q2 2016 and held it in 16 quarters.
- UBS Group's MyoKardia, Inc. Common Stock position peaked at $3.52M in Q3 2017.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.